natgillin/translations-raw huggingface dataset:
It is unknown whether palonosetron or netupitant are excreted in human milk.
Nije poznato izlučuju li se palonozetron ili netupitant u majčino mlijeko.
• ECG (electrocardiogram) problems (called ‘ST segment depression', ‘ST-T segment abnormal'
• tegobe vidljive na EKG-u (elektrokardiogramu) (koje se nazivaju depresija ST-segmenta,
Furthermore, the population PK study showed no correlation between PK parameters of netupitant and markers of renal dysfunction.
Nadalje, ispitivanje populacijske farmakokinetike nije pokazalo korelaciju između farmakokinetičkih parametara netupitanta i biljega poremećaja funkcije bubrega.
Palonosetron
Palonozetron
Netupitant/palonosetron capsules are unlikely to interact with medicinal products which are P-gp substrates.
Nije vjerojatna interakcija između netupitant/palonozetron kapsula i lijekova koji su supstrati P-gp-a.
This medicine contains less than 1 mmol sodium per (23 mg) per hard capsule, that is to say essentially ‘sodium-free'.
Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po tvrdoj kapsuli, tj. zanemarive količine natrija.
This medicinal product also contains 20 mg of sucrose in each capsule.
Ovaj lijek također sadrži 20 mg saharoze u jednoj kapsuli.
Palonosetron is eliminated from the body through both renal excretion and metabolic pathways, with the latter mediated via multiple CYP enzymes.
Palonozetron se iz tijela eliminira i izlučivanjem putem bubrega i metaboličkim putevima, s tim da kod izlučivanja metaboličkim putevima posreduje više enzima CYP-a.
Approximately half the radioactivity administered orally as [14C]-netupitant was recovered from urine and faeces within 120 h of dosing.
Približno pola radioaktivnosti primijenjene peroralno kao [14C]-netupitant otkriveno je u mokraći i stolici unutar 120 h od primjene doze.
Moreover, this medicinal product should be used with caution in patients receiving concomitant orally administered active substances with a narrow therapeutic range that are primarily metabolized by CYP3A4, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, diergotamine, ergotamine, fentanyl, and quinidine.
Nadalje, ovaj lijek treba s oprezom davati bolesnicima koji istovremeno peroralno primaju djelatne tvari uske terapijske širine koje se primarno metaboliziraju putem CYP3A4, kao što su ciklosporin, takrolimus, sirolimus, everolimus, alfentanil, diergotamin, ergotamin, fentanil i kinidin.
Administration of the CYP3A4 inhibitor ketoconazole with netupitant/palonosetron capsules increased the AUC of netupitant 1.8 fold and Cmax 1.3 fold when compared to the administration of netupitant/palonosetron capsules alone.
Primjena ketokonazola, inhibitora CYP3A4, s netupitant/palonozetron kapsulama povećala je AUC netupitanta 1,8 puta, a Cmax 1,3 puta u usporedbi s primjenom samo netupitant/palonozetron kapsula.
In 82 healthy subjects given a single oral dose of netupitant 300 mg, maximum plasma netupitant concentration (Cmax) was 486 ±268 ng/mL (mean ± SD) and median time to maximum concentration (Tmax) was 5.25 hours, the AUC was 15032 ± 6858 h.ng/mL.
U 82 zdrava ispitanika koji su primili jednu peroralnu dozu netupitanta od 300 mg, maksimalna koncentracija netupitanta u plazmi (Cmax) bila je 486 ± 268 ng/ml (srednja vrijednost ± SD), medijan vremena do maksimalne koncentracije (Tmax) bio je 5,25 sati, a vrijednost AUC-a bila je 15032 ± 6858 h.ng/ml.
In a multicenter, randomized, parallel, double-blind, controlled clinical study of 694 patients, the efficacy and safety of single doses of oral netupitant in combination with oral palonosetron was compared with a single oral dose of palonosetron in cancer patients receiving a chemotherapy regimen that included cisplatin (median dose = 75 mg/m2).
U multicentričnom, randomiziranom, dvostruko slijepom, kontroliranom kliničkom ispitivanju sa 694 bolesnika u usporednim skupinama, uspoređena je djelotvornost i sigurnost jednostrukih doza peroralnog netupitanta u kombinaciji s peroralnim palonozetronom i jedne peroralne doze palonozetrona, u bolesnika s rakom na kemoterapijskom protokolu s cisplatinom (medijan doze = 75 mg/m2).
Interaction between oral netupitant and oral palonosetron:
Interakcija između peroralnog netupitanta i peroralnog palonozetrona:
• The active substances are palonosetron and netupitant.
• Djelatne tvari su palonozetron i netupitant.
• medicines with a narrow therapeutic range that are primarily metabolized by CYP3A4, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, diergotamine, ergotamine, fentanyl,
• lijekove uske terapijske širine koji se razgrađuju prvenstveno putem CYP3A4, kao što su ciklosporin, takrolimus, sirolimus, everolimus, alfentanil, diergotamin, ergotamin, fentanil ili kinidin
Limited data exist in patients with severe hepatic impairment (Child Pugh score ≥ 9).
Ograničeni su podaci u bolesnika s teškim oštećenjem funkcije jetre (Child Pugh rezultat ≥ 9).
This medicinal product should be used with caution in patients receiving concomitant orally administered active substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range (see section 4.5).
Ovaj lijek treba primjenjivati s oprezom u bolesnika koji istovremeno peroralno primaju djelatne tvari koje se metaboliziraju primarno putem CYP3A4 te imaju usku terapijsku širinu (vidjeti dio 4.5).
In particular tell your doctor, pharmacist or nurse if you are taking any of the following medicines:
Osobito je važno da liječnika, ljekarnika ili medicinsku sestru obavijestite ako uzimate neki od sljedećih lijekova:
A high fat meal did not affect the Cmax and AUC of oral palonosetron.
Obrok s visokim sadržajem masti nije utjecao na Cmax i AUC peroralnog palonozetrona.
Total systemic exposure to intravenous palonosetron increased by approximately 28% in patients with severe impairment relative to healthy subjects.
Ukupna sistemska izloženost intravenskom palonozetronu povećala se za približno 28% u bolesnika s teškim oštećenjem funkcije bubrega u odnosu na zdrave ispitanike.
When netupitant/palonosetron capsules are used concomitantly with another CYP3A4 inhibitor, netupitant plasma concentrations could be elevated.
Kada se netupitant/palonozetron kapsule uzimaju istovremeno s drugim inhibitorom CYP3A4, koncentracije netupitanta u plazmi mogu biti povišene.
Dialysis studies have not been performed.
Nisu provedena ispitivanja uklanjanja dijalizom.
Renal clearance is not a significant elimination route for netupitant-related entities.
Klirens putem bubrega nije značajan put eliminacije za tvari povezane s netupitantom.
In vitro data suggests that netupitant inhibits the efflux of transporter BCRP.
In vitro podaci upućuju na to da netupitant inhibira efluks prijenosnika BCRP.
Non-clinical studies indicate that netupitant and its metabolites and the combination with palonosetron only at very high concentrations may block ion channels involved in ventricular de- and re-polarisation and prolong action potential duration.
Neklinička ispitivanja pokazuju da netupitant i njegovi metaboliti te kombinacija s palonozetronom, samo u vrlo visokim koncentracijama mogu blokirati ionske kanale uključene u ventrikularnu depolarizaciju i repolarizaciju te produljiti trajanje akcijskog potencijala.
In a multicenter, randomized, parallel, double-blind, active-controlled, superiority study, the efficacy and safety of a single oral dose of Akynzeo was compared with a single oral dose of palonosetron 0.5 mg in cancer patients scheduled to receive the first cycle of an anthracycline and cyclophosphamide regimen for the treatment of a solid malignant tumor.
Ispitivanje umjereno emetogene kemoterapije (MEC) U multicentričnom, randomiziranom, dvostruko slijepom ispitivanju superiornosti na usporednim skupinama s aktivnom kontrolom, djelotvornost i sigurnost jedne peroralne doze Akynzea uspoređena je s jednom peroralnom dozom palonozetrona od 0,5 mg u bolesnika s rakom, za koje je bio planiran prvi ciklus protokola s antraciklinom i ciklofosfamidom za liječenje solidnog zloćudnog tumora.
• problems with the muscles in your heart (cardiomyopathy)
• tegobe sa srčanim mišićem (kardiomiopatija)
No data from animal studies with netupitant are available regarding placental transfer and lactation.
Nema podataka iz ispitivanja na životinjama za netupitant s obzirom na prijenos kroz posteljicu i laktaciju.
In healthy subjects given palonosetron capsules 0.5 mg, the terminal elimination half-life (t½) of palonosetron was 37 ± 12 hours (mean ± SD), and in cancer patients, t½ was 48 ± 19 hours.
U zdravih ispitanika koji su uzeli kapsule palonozetrona od 0,5 mg, terminalni poluvijek eliminacije (t½) palonozetrona iznosio je 37 ± 12 sati (srednja vrijednost ± SD), a u bolesnika s rakom, t½ je bio 48 ± 19 sati.
Neither netupitant nor palonosetron have been evaluated in patients with end-stage renal disease.
Primjena netupitanta i primjena palonozetrona nisu procijenjene u bolesnika sa završnim stadijem bubrežne bolesti.
The symptoms of overdose may include headache, dizziness, constipation, anxiety, palpitations, euphoric mood and pain in the legs.
Simptomi predoziranja mogu uključivati glavobolju, omaglicu, zatvor, tjeskobu, lupanje srca (palpitacije), euforično raspoloženje i bolove u nogama.
No specific studies were performed to evaluate netupitant in patients with renal impairment.
Nisu provedena posebna ispitivanja za procjenu netupitanta u bolesnika s oštećenjem funkcije bubrega.
Capsule shell Gelatin
Ovojnica kapsule želatina glicerol sorbitol
In 12 cancer patients given a single oral dose of palonosetron 0.5 mg one hour prior to chemotherapy, Cmax was 0.93 ± 0.34 ng/mL and Tmax was 5.1 ± 5.9 hours.
U 12 bolesnika s rakom koji su primili jednu peroralnu dozu palonozetrona u dozi od 0,5 mg jedan sat prije kemoterapije, Cmax je iznosio 0,93 ± 0,34 ng/ml, a Tmax 5,1 ± 5,9 sati.
Netupitant/palonosetron capsules should not be used during breast-feeding.
Netupitant/palonozetron kapsule ne smiju se primjenjivati u razdoblju dojenja.
If you stop taking Akynzeo
Ako prestanete uzimati Akynzeo
Blood and lymphatic system disorders
Poremećaji krvi i limfnog sustava neutropenija leukopenija leukocitoza limfocitoza
Hard capsule content:
Sadržaj tvrde kapsule:
In humans, netupitant is eliminated mainly by hepatic metabolism mediated by CYP3A4 with a marginal renal excretion.
U ljudi, netupitant se eliminira uglavnom metabolizmom u jetri posredovanim pomoću CYP3A4 uz minimalno izlučivanje putem bubrega.
Akynzeo 300 mg/0.5 mg hard capsules netupitant/palonosetron
Akynzeo 300 mg / 0,5 mg tvrde kapsule netupitant/palonozetron
Delayed phase
Odgođena faza Cijela faza
By blocking the actions of substance P and serotonin in this way, the medicines help prevent the stimulation of the vomiting centre and the resulting sickness.
P i serotonina, lijek pomaže u sprječavanju poticanja centra za povraćanje i posljedične mučnine.
If you forget to take Akynzeo
Ako ste zaboravili uzeti Akynzeo
Talk to your doctor, pharmacist or nurse before taking Akynzeo if: • you have liver problems
Obratite se liječniku, ljekarniku ili medicinskoj sestri prije nego što uzmete Akynzeo ako:
‘bundle branch block right/left', and ‘atrioventricular block second degree')
abnormalan ST-T segment, blok desnog/lijevog snopa grane i atrioventrikularni blok drugog stupnja).
As palonosetron may increase large bowel transit time, patients with a history of constipation or signs of subacute intestinal obstruction should be monitored following administration (see section
Budući da palonozetron može produljiti vrijeme prolaska stolice kroz debelo crijevo, bolesnike s anamnezom konstipacije ili znakovima subakutne crijevne opstrukcije treba nakon primjene nadzirati (vidjeti dio 4.8).
No consistent effect was seen with cyclophosphamide after netupitant co-administration.
Takav učinak nije opažen s ciklofosfamidom nakon istovremene primjene s netupitantom.
The recommended oral dexamethasone dose should be reduced by approximately 50 % when coadministered with netupitant/palonosetron capsules (see section 4.5 and clinical studies administration schedule in section 5.1).
Kad se primjenjuje istovremeno s netupitant/palonozetron kapsulama, preporučena doza peroralnog deksametazona treba biti snižena za približno 50% (vidjeti dio 4.5 i raspored primjene u kliničkim ispitivanjima u dijelu 5.1).
Overall phase No emesis
Bez emeze
In 36 healthy male and female subjects given a single oral dose of 0.5 mg palonosetron, maximum plasma concentration (Cmax) was 0.81 ± 1.66 ng/mL (mean ± SD) and time to maximum concentration (Tmax) was 5.1 ± 1.7 hours.
U 36 zdravih muškaraca i žena koji su primili jednu peroralnu dozu palonozetrona od 0,5 mg, maksimalna koncentracija palonozetrona u plazmi (Cmax) bila je 0,81 ± 1,66 ng/ml (srednja vrijednost ± SD), a vrijeme do maksimalne koncentracije (Tmax) iznosilo je 5,1 ± 1,7 sati.
Netupitant and combination with palonosetron
Netupitant i kombinacija s palonozetronom
Other side effects Tell your doctor, pharmacist or nurse if you notice any of the following side effects:
Ostale nuspojave Obavijestite svoga liječnika, ljekarnika ili medicinsku sestru ako uočite neku od sljedećih nuspojava:
• dexamethasone - can be used to treat feeling and being sick
• deksametazon - može se koristiti za liječenje mučnine i povraćanja
Consequently, concomitant administration with strong CYP3A4 inhibitors (e.g., ketoconazole) should be approached with caution and concomitant administration with strong CYP3A4 inducers (e.g. rifampicin) should be avoided.
Zbog toga istovremenoj primjeni s jakim inhibitorima CYP3A4 (npr. ketokonazolom) treba pristupati oprezno, a istovremenu primjenu s jakim induktorima CYP3A4 (npr. rifampicinom) treba izbjegavati.
This medicinal product may contain a trace of lecithin derived from soya.
Ovaj lijek može sadržavati u tragovima lecitin dobiven od soje.
135 patients who received a single oral dose (netupitant 300 mg and palonosetron 0.5 mg) and 136 patients who received oral palonosetron 0.5 mg alone.
Djelotvornost Akynzea procijenjena je u 135 bolesnika koji su primili jednu peroralnu dozu (netupitant 300 mg i palonozetron 0,5 mg) te 136 bolesnika koji su primili samo peroralni palonozetron u dozi od 0,5 mg.
Therefore, caution is recommended when netupitant is combined with digoxin or with other P-gp substrates such as dabigatran, or colchicine.
Stoga se preporučuje oprez kada se netupitant kombinira s digoksinom ili s drugim supstratima
Akynzeo 300 mg/0.5 mg hard capsules
Akynzeo 300 mg/0,5 mg tvrde kapsule
Helsinn Birex Pharmaceuticals Ltd. Damastown, Mulhuddart Dublin 15,
Damastown, Mulhuddart Dublin 15
As such, no dosage adjustment is necessary for patients with mild to moderate hepatic impairment.
S obzirom na to, prilagodba doze nije potrebna u bolesnika s blagim do umjerenim oštećenjem funkcije jetre.
Total systemic exposure to intravenous palonosetron increased by approximately 28% in severe renal impairment relative to healthy subjects.
Ukupna sistemska izloženost intravenskom palonozetronu povećala se približno 28% u bolesnika s teškim oštećenjem funkcije bubrega u odnosu na zdrave ispitanike.
What Akynzeo contains
Što Akynzeo sadrži
After a single dose of approximately 0.75 mg intravenous palonosetron, the total body clearance of palonosetron in healthy subjects was 160 ± 35 mL/h/kg (mean ± SD) and renal clearance was 66.5± 18.2 mL/h/kg.
Nakon jedne doze od približno 0,75 mg intravenski primijenjenog palonozetrona, ukupni tjelesni klirens palonozetrona u zdravih ispitanika iznosio je 160 ± 35 ml/h/kg (srednja vrijednost ± SD), a bubrežni klirens 66,5 ± 18,2 ml/h/kg.
QT Prolongation
Produljenje QT intervala
Mild to moderate renal impairment does not significantly affect palonosetron pharmacokinetic parameters.
Blago do umjereno oštećenje funkcije bubrega ne utječe značajno na farmakokinetičke parametre palonozetrona.
Palonosetron is mainly metabolised by CYP2D6, with minor contribution by CYP3A4 and CYP1A2 isoenzymes.
Palonozetron se uglavnom metabolizira putem CYP2D6, uz manji doprinos izoenzima CYP3A4 i CYP1A2.
What Akynzeo is
Što je Akynzeo
• numbness, blurred vision
• utrnutost, zamućen vid
Adverse reactions are listed below by MedDRA body system organ class and frequency.
Nuspojave su navedene u nastavku prema MedDRA-inoj klasifikaciji organskih sustava i učestalosti.
The signs may include hives, itch, angioedema, low blood pressure, throat tightness, chest tightness, dyspnoea, loss of consciousness.
Znakovi mogu uključivati koprivnjaču, svrbež, angioedem, nizak krvni tlak, stezanje u grlu, stezanje u prsnom košu, dispneju, gubitak svijesti.
Inhibition of the efflux transported BCRP and glucuronidation isozyme UGT2B7 by netupitant and its metabolites is unlikely and, if it occurs, of scarce clinical relevance.
Nije vjerojatno da će netupitant i njegovi metaboliti inhibirati efluksni prijenosnik BCRP i izoenzim glukuronidacije UGT2B7 i, ako se to dogodi, od male je kliničke značajnosti.
In vitro metabolism studies have suggested that CYP3A4 and, to a lesser extent, CYP2D6 and CYP2C9 are involved in the metabolism of netupitant.
Ispitivanja metabolizma in vitro ukazala su na sudjelovanje CYP3A4, a u manjoj mjeri CYP2D6 i CYP2C9 u metabolizmu netupitanta.
Akynzeo is used to help prevent adults with cancer feeling sick (nausea) or being sick (vomiting) while having cancer treatment called ‘chemotherapy'.
Akynzeo se primjenjuje kako bi se u odraslih osoba s rakom spriječila mučnina ili povraćanje za vrijeme liječenja protiv raka koje se naziva „kemoterapija“.
How to take Akynzeo
Kako uzimati Akynzeo
Netupitant tablets Microcrystalline cellulose (E460) Sucrose lauric acid esters Povidone K-30
Netupitant tablete mikrokristalična celuloza (E460) saharozni esteri lauratne kiseline povidon K-30 umrežena karmelozanatrij koloidni hidratizirani silicijev dioksid natrijev stearilfumarat magnezijev stearat
• high levels of creatine phosphokinase/ creatine phosphokinase MB - which indicates sudden decreased blood flow to the heart muscle (shown in blood tests)
• visoke razine kreatin fosfokinaze/kreatin fosfokinaze MB - što ukazuje na iznenadni smanjeni priljev krvi u srčani mišić (prema pretragama krvi)
Chemotherapeutic medicinal products (docetaxel, etoposide, cyclophosphamide) Exposure to docetaxel and etoposide was increased 37% and 21%, respectively, when co-administered with netupitant/palonosetron capsules.
Kemoterapijski lijekovi (docetaksel, etopozid, ciklofosfamid) Kod istovremene primjene s netupitant/palonozetron kapsulama, izloženost docetakselu povećala se 37%, a etopozidu 21%.
Table 2: Oral Antiemetic treatment regimen -- HEC study
Tablica 2: Režim liječenja peroralnim antiemeticima - ispitivanje visoko emetogene kemoterapije (HEC)
Table 4: Oral Antiemetic treatment regimen - MEC study
Tablica 4: Režim liječenja peroralnim antiemeticima - ispitivanje umjereno emetogene kemoterapije (MEC)
• stomach problems including stomach discomfort, feeling bloated, nausea, pain, indigestion,
• tegobe sa želucem uključujući nelagodu u želucu, osjećaj nadutosti, mučninu, bol, probavne tegobe, štucanje, vjetrove ili proljev
Rare: (may affect up to 1 in 1,000 people)
Rijetko: (mogu se javiti u manje od 1 na 1000 osoba)
Co-administration with ketoconazole did not affect the pharmacokinetics of palonosetron.
Istovremena primjena ketokonazola nije utjecala na farmakokinetiku palonozetrona.
It may also contain a trace of lecithin derived from soya.
Ovaj lijek može također sadržavati u tragovima lecitin dobiven od soje.
Co-administration of rifampicin did not affect the pharmacokinetics of palonosetron.
Istovremena primjena rifampicina nije utjecala na farmakokinetiku palonozetrona.
Palonosetron Degeneration of seminiferous epithelium has been observed in rat study (see section 5.3).
U ispitivanju na štakorima opažena je degeneracija sjemenskog epitela (vidjeti dio 5.3).
Major secondary endpoints Complete response Acute phase
Primarni ishod Potpuni odgovor Odgođena faza Glavni sekundarni ishodi Potpuni odgovor Akutna faza Cijela faza§
What Akynzeo is used for
Za što se Akynzeo koristi
Akynzeo is indicated in adults for the: - Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy.
Akynzeo je indiciran u odraslih za: - sprječavanje akutne i odgođene mučnine i povraćanja povezanih s visoko emetogenom kemoterapijom protiv raka na bazi cisplatina - sprječavanje akutne i odgođene mučnine i povraćanja povezanih s umjereno emetogenom kemoterapijom protiv raka.
Therefore, Akynzeo can be administered without dosage adjustment in patients with renal impairment.
Stoga se u bolesnika s oštećenjem funkcije bubrega Akynzeo može primjenjivati bez prilagodbe doze.
Akynzeo (Netupitant 300 mg + Palonosetron 0.5 mg) Dexamethasone 12 mg
Akynzeo (netupitant 300 mg + palonozetron 0,5 mg) deksametazon 12 mg deksametazon 8 mg jedanput na dan
• high level of ‘lymphocytes'- type of white blood cell which help the body fight disease (shown in blood tests)
• visoka razina limfocita - vrsta bijelih krvnih stanica koja pomaže tijelu u suzbijanju bolesti
Decreased appetite Hypokalaemia
Poremećaji metabolizma i prehrane oslabljen apetit hipokalemija
Animal data do not indicate direct or indirect harmful effects of palonosetron with the respect to reproductive toxicity (see section
Podaci dobiveni na životinjama ne ukazuju na izravan ili neizravan štetan učinak palonozetrona na reprodukciju (vidjeti dio 5.3).
What you need to know before you take Akynzeo
Što morate znati prije nego počnete uzimati Akynzeo Nemojte uzeti Akynzeo:
Akynzeo is taken to help prevent you feeling and being sick when you are having chemotherapy.
Akynzeo se uzima da spriječi mučninu i povraćanje dok primate kemoterapiju.
Netupitant is a selective antagonist of human substance P/neurokinin 1 (NK1) receptors.
P/ neurokinina 1 (NK1) u ljudi.
Back pain Pain in extremities
• bol u leđima, bol u zglobovima
The signs may include hives, skin rash, itching, difficulty breathing or swallowing, swollen mouth, face, lips, tongue or throat and sometimes a drop-in blood pressure.
Znakovi mogu uključivati koprivnjaču, osip na koži, svrbež, otežano disanje ili gutanje, otečena usta, lice, usne, jezik ili grlo, a katkad sniženje krvnog tlaka.
• medicines for depression or anxiety called SNRIs (serotonin noradrenaline re-uptake inhibitors)
• lijekove protiv depresije ili tjeskobe, zvane inhibitori ponovne pohrane serotonina i noradrenalina (SNRI) - kao što su venlafaksin ili duloksetin.
Delayed emesis has been associated with the activation of tachykinin family neurokinin 1 (NK1) receptors (broadly distributed in the central and peripheral nervous systems) by substance P. As shown in in vitro and in vivo studies, netupitant inhibits substance P mediated responses.
P koja aktivira receptore neurokinina 1 (NK1) iz obitelji tahikinina (široko rasprostranjeni u središnjem i perifernom živčanom sustavu).
• low levels of ‘neutrophils' - a kind of white blood cell which fight infections (shown in blood tests)
• niske razine neutrofila - vrste bijelih krvnih stanica koje suzbijaju infekcije (prema pretragama krvi)
Treatment regimens for the Akynzeo and the palonosetron 0.5 mg arms are displayed in Table below.
U tablici ispod prikazani su terapijski režimi skupina koje su primale Akynzeo i palonozetron 0,5 mg.
In vitro metabolism studies have suggested that CYP2D6 and to a lesser extent, CYP3A4 and CYP1A2 are involved in the metabolism of palonosetron.
Ispitivanja metabolizma in vitro ukazala su na sudjelovanje CYP2D6, a u manjoj mjeri CYP3A4 i CYP1A2 u metabolizmu palonozetrona.
Chemotherapy medicines can cause the body to release substances called serotonin and substance P. This stimulates the vomiting centre in the brain, making you feel or be sick.
Kemoterapijski lijekovi mogu u tijelu prouzročiti otpuštanje tvari pod nazivom serotonin i tvar P.
How Akynzeo works
Kako Akynzeo djeluje
• haemorrhoids
• osjećaj omamljenosti
Flushing Hypotension
Krvožilni poremećaji hipertenzija navale crvenila hipotenzija
How to store Akynzeo
Kako čuvati Akynzeo
• high levels of the pigment bilirubin - which indicates liver dysfunction (shown in blood tests)
• visoke razine pigmenta bilirubina - što ukazuje na poremećaj funkcije jetre (prema pretragama krvi)
• low level of white blood cells (shown in blood tests)
• niska razina bijelih krvnih stanica (prema pretragama krvi)